- The U.S. compounding pharmacy market is projected to grow from $6.04 billion in 2026 to $12.79 billion by 2036.
- Future Market Insights forecasts a 7.8% compound annual growth rate during the period.
- Veterinary medicine was identified as a key therapeutic segment alongside pain management, dermatology, pediatrics and hormone replacement therapy.
- Demand is being driven by growing use of personalized medications, specialized dosage forms and solutions for drug shortages.
- The Midwest is expected to be among the fastest-growing regions, supported in part by veterinary healthcare demand.
Veterinary medicine is expected to play an increasingly important role in the growth of the U.S. compounding pharmacy sector, according to a new report from Future Market Insights (FMI).
The research projects the U.S. compounding pharmacy market will expand from $6.04 billion in 2026 to $12.79 billion by 2036, representing a compound annual growth rate of 7.8%.
While compounded medications serve a broad range of human healthcare specialties, FMI identified veterinary medicine as one of the market’s primary therapeutic growth areas. Demand is being fueled by the need for customized dosage strengths, flavor-enhanced formulations, alternative delivery methods and medications that may not be commercially available.
Personalized Medicine Expands Beyond Human Healthcare
Compounding pharmacies are increasingly being used to address patient-specific treatment needs across multiple medical disciplines, including pain management, hormone replacement therapy, dermatology, pediatrics and veterinary medicine.
According to the report, healthcare providers are turning to compounded medications to improve treatment adherence, address drug shortages and provide formulations tailored to individual patient requirements.
For veterinary medicine, compounding can help clinicians manage species-specific dosing requirements, improve palatability and provide treatment options when approved commercial products are unavailable.
Market Outlook
FMI expects 503A pharmacies to remain the dominant segment of the market, accounting for approximately 65% of demand in 2026. Oral medications are projected to represent the largest product category.
Regionally, the South is forecast to be the fastest-growing market, while the Midwest is expected to see strong growth driven in part by veterinary healthcare demand and healthcare infrastructure expansion.
The report also highlights continued investment in sterile compounding capabilities, personalized medicine services and specialty pharmacy operations as companies position themselves for long-term growth.
Information sourced from the Future Market Insights market report. Market forecasts and projections are forward-looking estimates subject to change.
